Our BLOG

Unconventional Resumes – Don’t Do It! {Slideshare}

Share it
Facebook
Twitter
LinkedIn
Email

  1. Unconventional Resumes – DON’T DO IT!
  2. You’ve worked hard.
  3. Your education, experience and skills are in line with the job you are applying for.
  4. You’ve created a clear and concise resume that accurately reflects this.
  5. But, something’s missing.
  6. How do you make your resume stand out from the 500 other applicants?
  7. How about turning your resume into an infographic, video or SlideShare?
  8. What about an online or website resume?
  9. DON’T DO IT!
  10. In a recent study, 78% of advertising and marketing executives interviewed said they would rather receive traditional CVs in Word or PDF format.
  11. Along with that…
  12. Unconventional resumes are annoying and can’t be read by Applicant Tracking Systems!
  13. Unconventional Resumes are Annoying!
  14. On average, a Human Resources professional or hiring manage will review your resume for 8 seconds!
  15. If they can’t find your current position or your skills section in that 8 seconds because of all the creativity going on, you just got DELETED.
  16. The judicious use of keywords that apply to you and the position you are applying for will be far more effective in holding their interest.
  17. Also, beauty is in the eye of the beholder.
  18. What you think is attractive, creative and colorful in your unconventional resume, another might see as tacky, garish and too informal.
  19. Unconventional Resumes Can’t Be Read by Applicant Tracking Systems!
  20. Almost all large corporations and many mid-size firms use applicant tracking systems to sort and store past applications.
  21. If the software can’t easily load your unconventional resume, once again, your resume is DELETED.

Interested in starting a job search or hiring?  Contact Smith Hanley Associates‘ Partner, Jacque Paige, at jpaige@smithhanley.com.

Share it
Facebook
Twitter
LinkedIn
Email

Related Posts

obesity drug impact

The Obesity Drug Impact

Sales of GLP-1 agonists obesity drugs Ozempic and Wegovy, which are semaglutides, and Mounjaro and Zepbound, which are tirzepatides, were $6 billion in 2023. Morgan

Read More »